Signaturefd LLC Grows Position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Signaturefd LLC raised its holdings in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) by 883.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,949 shares of the company’s stock after buying an additional 2,649 shares during the quarter. Signaturefd LLC’s holdings in Fusion Pharmaceuticals were worth $28,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. abrdn plc purchased a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $209,000. Federated Hermes Inc. grew its holdings in shares of Fusion Pharmaceuticals by 1.9% during the fourth quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock worth $104,616,000 after buying an additional 202,364 shares in the last quarter. HealthInvest Partners AB purchased a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $1,201,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $80,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $299,000. Hedge funds and other institutional investors own 72.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on FUSN. SVB Leerink reaffirmed a “market perform” rating and set a $21.00 target price (up previously from $17.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Truist Financial reissued a “hold” rating and issued a $21.00 price objective (up previously from $11.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. William Blair lowered shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 19th. Royal Bank of Canada reissued a “sector perform” rating and issued a $21.00 price objective (up previously from $16.00) on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Finally, Wedbush lowered shares of Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 price objective for the company. in a report on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $20.25.

Fusion Pharmaceuticals Trading Down 0.2 %

NASDAQ FUSN opened at $21.45 on Friday. The firm’s 50-day moving average is $17.73 and its two-hundred day moving average is $10.95. Fusion Pharmaceuticals Inc. has a 12 month low of $2.31 and a 12 month high of $21.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01. The stock has a market capitalization of $1.82 billion, a P/E ratio of -14.59 and a beta of -0.69.

Fusion Pharmaceuticals (NASDAQ:FUSN) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. On average, sell-side analysts anticipate that Fusion Pharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Fusion Pharmaceuticals Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.